ADC Biotechnology Ltd was established in 2010 with the aim of developing and marketing advanced conjugation technologies for the Antibody Drug Conjugate market. Our exclusive 'Lock-Release'? technology enables bioconjugation by immobilizing proteins on solid supports, providing several significant product benefits such as minimal aggregate formation, reduced residual free drug, and improved yields. The application of our 'Lock-Release'? platform, from fundamental R&D to enhanced supply economics and product risk management, adds value by delivering superior products with increased efficiency.